PACUPod: Cardiology
Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction summary
Nov 18, 20258 minS0
Loading…
Loading…
health
Hosted by Pharmacy & Acute Care University · health · EN · 19 episodes
PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across cardiology pharmacotherapy and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
26%
Guest openness
Selective
Sign up to generate a grounded pitch for PACUPod: Cardiology.
Signup to Generate a PitchPACUPod: Cardiology is a health podcast hosted by Pharmacy & Acute Care University, with 19 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.
Pharmacy & Acute Care University hosts PACUPod: Cardiology, a health show with 19 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
PACUPod: Cardiology
PACUPod: Cardiology
<p>This PACUPod episode reviews Wu et al.'s randomized trial in JAMA Network Open evaluating early cardiac rehabilitation initiated during the CICU for patients with acute decompensated heart failure. In this single-center study of 120 high-risk CICU patients, participants were randomized to an early, progressive, personalized cardiac rehab program during CICU stay (AHF-CR) or to usual care without structured early rehab. Primary outcomes were discharge Short Physical Performance Battery (SPPB) score and six-month all-cause rehospitalization; exploratory outcome included the Perme ICU Mobility score during the CICU stay. Results showed no significant difference in discharge SPPB (median difference 1.0 point; 95% CI crossed...
PACUPod: Cardiology
<p>In this episode, hosts Britany and Seth unpack the prospective Murcia AF Project III (MAFP-III) cohort study, which investigates remnant cholesterol (RC) and LDL-C discordance as predictors of thromboembolic events in patients with atrial fibrillation on oral anticoagulation. They explain how RC reflects triglyceride-rich lipoproteins (VLDL/IDL), how RC is calculated from standard lipid panels (total cholesterol minus LDL-C minus HDL-C), and the main finding: elevated RC predicts higher thromboembolic risk particularly when LDL-C is low. Over an average follow-up of about 1.86 years, the study reports an adjusted hazard ratio of 1.82 (95% CI 1.03–3.23, p=0.039) for thromboembolic events in the low-LDL-C gr...
PACUPod: Cardiology
<p>Myocardial bridge (MB) is a common congenital coronary anomaly where a coronary artery tunnels through the myocardium, causing systolic compression. This PACUPod overview examines whether single antiplatelet therapy (APT), such as aspirin, provides ischemic protection for MB patients without other indications, and how the RIALTO registry informs clinical practice. The ambispective study analyzed 221 MB patients after excluding those with established APT or anticoagulation indications, comparing mostly aspirin at discharge versus no APT over a median follow-up of 4.5 years. The primary outcome, net adverse clinical events (NACE), combined cardiovascular death, nonfatal MI, need for coronary imaging, ischemic stroke, and bleeding...
PACUPod: Cardiology
<p>This PACUPod episode reviews a secondary analysis of the SUMMIT trial investigating how baseline adiposity (BMI and central adiposity via waist-height ratio) and weight loss influence tirzepatide's benefits in obesity-related HFpEF. The discussion covers study design, primary outcome (time to cardiovascular death or worsening heart failure), and secondary outcomes (KCCQ-CSS, six-minute walk distance, CRP, body weight, and systolic blood pressure). Tirzepatide reduced the primary endpoint across all BMI and WHR tertiles, while improvements in functional and inflammatory markers varied with adiposity. Central adiposity identified higher-risk subgroups beyond BMI, and greater weight loss correlated with better 6MWD, quality of life...
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
